García-García E, Mancillas-Adame L

Language: Spanish
References: 9
Page: 132-134
PDF size: 209.73 Kb.

Text Extraction

No abstract

REFERENCES

1. Bray GA. To treat or not to treat: that is the question. Obes Res 1997; 5: 634-635.

2. Korner J, Leibel RL. To eat or not to eat-how the gut talks to the brain. N Engl J Med 2003; 349: 926-928.

3. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated metaanalysis. BMJ 2007; 335: 1194–1199.

4. James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz ChL, for the SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-917.

5. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ. Randomized trial old lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-2120.

6. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diab Care 2004; 27: 155-161.

7. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007; 176: 1-117 Online.

8. Obesity guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children NICE clinical guideline 43. Developed by the National Collaborating Centre for Primary Care and the Centre for Public Health Excellence at NICE (www.nice.org. uk/CG043fullguideline) and the National Library for Health (www.nlh.nhs.uk).

9. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: Past, current, and future therapies. J Obes 2011; 179674. Epub 2010 Dec 12.